Literature DB >> 16157560

A role for G(z) in pancreatic islet beta-cell biology.

Michelle E Kimple1, Andrew B Nixon, Patrick Kelly, Candice L Bailey, Kenneth H Young, Timothy A Fields, Patrick J Casey.   

Abstract

Glucose-stimulated insulin secretion and beta-cell growth are important facets of pancreatic islet beta-cell biology. As a result, factors that modulate these processes are of great interest for the potential treatment of Type 2 diabetes. Here, we present evidence that the heterotrimeric G protein G(z) and its effectors, including some previously thought to be confined in expression to neuronal cells, are present in pancreatic beta-cells, the largest cellular constituent of the islets of Langerhans. Furthermore, signaling pathways upon which G alpha(z) impacts are intact in beta-cells, and G alpha(z) activation inhibits both cAMP production and glucose-stimulated insulin secretion in the Ins-1(832/13) beta-cell-derived line. Inhibition of glucose-stimulated insulin secretion by prostaglandin E (PGE1) is pertussis-toxin insensitive, indicating that other G alpha(i) family members are not involved in this process in this beta-cell line. Indeed, overexpression of a selective deactivator of G alpha(z), the RGS domain of RGSZ1, blocks the inhibitory effect of PGE1 on glucose-stimulated insulin secretion. Finally, the inhibition of glucose-stimulated insulin secretion by PGE1 is substantially blunted by small interfering RNA-mediated knockdown of G alpha(z) expression. Taken together, these data strongly imply that the endogenous E prostanoid receptor in the Ins-1(832/13) beta-cell line couples to G(z) predominantly and perhaps even exclusively. These data provide the first evidence for G(z) signaling in pancreatic beta-cells, and identify an endogenous receptor-mediated signaling process in beta-cells that is dependent on G alpha(z) function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16157560     DOI: 10.1074/jbc.M506700200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Hormonal inhibition of endocytosis: novel roles for noradrenaline and G protein G(z).

Authors:  Ying Zhao; Qinghua Fang; Susanne G Straub; Manfred Lindau; Geoffrey W G Sharp
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

2.  Rap1 promotes multiple pancreatic islet cell functions and signals through mammalian target of rapamycin complex 1 to enhance proliferation.

Authors:  Patrick Kelly; Candice L Bailey; Patrick T Fueger; Christopher B Newgard; Patrick J Casey; Michelle E Kimple
Journal:  J Biol Chem       Date:  2010-03-25       Impact factor: 5.157

3.  A method for mouse pancreatic islet isolation and intracellular cAMP determination.

Authors:  Joshua C Neuman; Nathan A Truchan; Jamie W Joseph; Michelle E Kimple
Journal:  J Vis Exp       Date:  2014-06-25       Impact factor: 1.355

Review 4.  Regulation of pancreatic β-cell function and mass dynamics by prostaglandin signaling.

Authors:  Bethany A Carboneau; Richard M Breyer; Maureen Gannon
Journal:  J Cell Commun Signal       Date:  2017-01-28       Impact factor: 5.782

Review 5.  Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus.

Authors:  Rachel J Fenske; Michelle E Kimple
Journal:  Exp Biol Med (Maywood)       Date:  2018-03-04

6.  Deletion of GαZ protein protects against diet-induced glucose intolerance via expansion of β-cell mass.

Authors:  Michelle E Kimple; Jennifer B Moss; Harpreet K Brar; Taylor C Rosa; Nathan A Truchan; Renee L Pasker; Christopher B Newgard; Patrick J Casey
Journal:  J Biol Chem       Date:  2012-03-28       Impact factor: 5.157

Review 7.  The EP3 Receptor/Gz Signaling Axis as a Therapeutic Target for Diabetes and Cardiovascular Disease.

Authors:  Michael D Schaid; Jaclyn A Wisinski; Michelle E Kimple
Journal:  AAPS J       Date:  2017-06-05       Impact factor: 4.009

8.  The Inhibitory G Protein α-Subunit, Gαz, Promotes Type 1 Diabetes-Like Pathophysiology in NOD Mice.

Authors:  Rachel J Fenske; Mark T Cadena; Quincy E Harenda; Haley N Wienkes; Kathryn Carbajal; Michael D Schaid; Erin Laundre; Allison L Brill; Nathan A Truchan; Harpreet Brar; Jaclyn Wisinski; Jinjin Cai; Timothy E Graham; Feyza Engin; Michelle E Kimple
Journal:  Endocrinology       Date:  2017-06-01       Impact factor: 4.736

9.  The EP3 Receptor: Exploring a New Target for Type 2 Diabetes Therapeutics.

Authors:  Joshua C Neuman; Michelle E Kimple
Journal:  J Endocrinol Diabetes Obes       Date:  2013 Jul-Sep

10.  Synergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes.

Authors:  Allison L Brill; Jaclyn A Wisinski; Mark T Cadena; Mary F Thompson; Rachel J Fenske; Harpreet K Brar; Michael D Schaid; Renee L Pasker; Michelle E Kimple
Journal:  Mol Endocrinol       Date:  2016-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.